Article
Pharmacology & Pharmacy
Ryan J. Keenan, Heather Daykin, Jiahui Chu, Linda Cornthwaite-Duncan, Giancarlo Allocca, Daniel Hoyer, Laura H. Jacobson
Summary: This study investigates the effects of sleep-promoting compounds in transgenic mouse models of tauopathy and finds that these compounds can effectively improve sleep disturbances. The results also suggest that there may be gender differences in the response to hypnotics, which could have implications for the treatment of neurodegenerative disorders in humans.
BRITISH JOURNAL OF PHARMACOLOGY
(2022)
Article
Cell Biology
Andrew S. Huhn, Patrick H. Finan, Charlene E. Gamaldo, Alexis S. Hammond, Annie Umbricht, Cecilia L. Bergeria, Eric C. Strain, Kelly E. Dunn
Summary: This study examined the use of a dual-orexin receptor antagonist in opioid withdrawal and found that it may have potential benefits for improving sleep and withdrawal outcomes.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Clinical Neurology
Brendan P. Lucey, Haiyan Liu, Cristina D. Toedebusch, David Freund, Tiara Redrick, Samir L. Chahin, Kwasi G. Mawuenyega, James G. Bollinger, Vitaliy Ovod, Nicolas R. Barthelemy, Randall J. Bateman
Summary: In this study, it was found that suvorexant, a dual orexin receptor antagonist, acutely decreased tau phosphorylation and amyloid-beta concentrations in the central nervous system. This suggests that suvorexant may have potential as a repurposed drug for the prevention of Alzheimer's disease.
ANNALS OF NEUROLOGY
(2023)
Article
Clinical Neurology
Mike Ufer, Debra Kelsh, Kerri A. Schoedel, Jasper Dingemanse
Summary: This study evaluated the abuse potential of daridorexant in healthy recreational sedative drug users. The results showed dose-related drug-liking effects of daridorexant, with lower effects at the highest dose and similar effects at higher doses compared to supratherapeutic doses of suvorexant and zolpidem. The safety and pharmacokinetics of daridorexant were consistent with earlier trials, with quick absorption and elimination.
Article
Urology & Nephrology
Magdalene M. Assimon, Jennifer E. Flythe
Summary: This study found that among patients receiving maintenance hemodialysis, the use of zolpidem compared to trazodone for treating insomnia was associated with a higher risk of hospitalized fall-related fractures.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2021)
Article
Chemistry, Organic
Hongshun Yuan, Lei Guo, Xianhua Pan
Summary: An efficient synthetic route for suvorexant without using chiral HPLC separation, resolution, enzyme catalysis or transition metal catalysis is reported, with a total yield up to 37%.
Article
Chemistry, Multidisciplinary
Mohammed H. Alqarni, Muzaffar Iqbal, Ahmed I. Foudah, Tariq M. Aljarba, Fatma Abdel Bar, Sultan Alshehri, Faiyaz Shakeel, Prawez Alam
Summary: Suvorexant is a new sedative/hypnotic medication, and this study proposed and validated a sensitive and rapid HPTLC bioanalytical method for determining its concentration in human urine samples.
Article
Clinical Neurology
Shadab A. Rahman, Margo D. Nathan, Aleta Wiley, Sybil Crawford, Aviva Y. Cohn, Jessica A. Harder, Leilah K. Grant, Athena Erickson, Akanksha Srivastava, Kathleen McCormick, Suzanne M. Bertisch, John W. Winkelman, Hadine Joffe
Summary: This study suggests that suvorexant is a well-tolerated and effective treatment option for VMS-associated insomnia disorder, reducing nighttime VMS symptoms. However, it did not significantly improve daytime VMS symptoms or other sleep-related outcomes.
Article
Behavioral Sciences
William W. Stoops, Justin C. Strickland, Kevin W. Hatton, Lon R. Hays, Abner O. Rayapati, Joshua A. Lile, Craig R. Rush
Summary: This study aimed to investigate the impact of orexin antagonists on cocaine restraint behavior. The results showed that suvorexant attenuated motivation for cocaine and cocaine conditioned place preference in rodents, and increased self-administration of 10 mg/70 kg cocaine in humans while decreasing oral temperature.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
(2022)
Article
Neurosciences
Parimal Chavan, Sachiko Chikahisa, Tetsuya Shiuchi, Noriyuki Shimizu, Junhel Dalanon, Kazuo Okura, Hiroyoshi Sei, Yoshizo Matsuka
Summary: The study found that predictable chronic mild stress (PCMS) activates orexin neuronal activity in the hypothalamus, and the use of a dual orexin receptor antagonist called suvorexant can help attenuate PCMS-induced thermal and mechanical hyperalgesia.
BRAIN RESEARCH BULLETIN
(2022)
Article
Pharmacology & Pharmacy
Jessica M. M. Illenberger, Francisco J. J. Flores-Ramirez, Alessandra Matzeu, Barbara J. J. Mason, Remi Martin-Fardon
Summary: This study showed that suvorexant can reduce self-administration and relapse of prescription opioids, especially in females.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Neurosciences
Carlos Carrera-Canas, Isabel de Andres, Marta Callejo, Miguel Garzon
Summary: The hypothalamic hypocretinergic/orexinergic system plays a role in various physiological processes, and dysfunction of this system leads to narcolepsy. This study used the drug suvorexant to block Hcrt/Ox transmission in rats and observed changes in body weight, cerebrospinal fluid levels of Hcrt1/OxA, and levels of Hcrt/Ox receptors in the hypothalamus. The results showed that blocking Hcrt/Ox transmission caused weight gain, decreased Hcrt1/OxA levels, and overexpression of Hcrt/OxR1 in the hypothalamus.
FRONTIERS IN MOLECULAR NEUROSCIENCE
(2022)
Article
Medicine, Research & Experimental
Diana T. Amari, Timothy R. Juday, Feride H. Frech, Weiying Wang, Deval Gor, Norman Atkins, Emerson M. Wickwire
Summary: Insomnia treatment increases the risk of falls, healthcare resource utilization, and costs. Patients treated with trazodone have the highest risk among the different treatments. The findings highlight the need for new treatment options to enhance the quality of care for patients with insomnia.
ADVANCES IN THERAPY
(2022)
Article
Clinical Neurology
Hiroyuki Sawatari, Tomoko Yoshikawa, Shin-ichi Ando
Summary: This study investigated the impact of zolpidem and lemborexant on sleep and morning symptoms in patients with suspected sleep-disordered breathing. The results showed that lemborexant increased rapid eye movement sleep, while zolpidem led to higher frequency of morning unsteadiness. Low-dose lemborexant administered during polysomnography may be a suitable option.
SLEEP AND BIOLOGICAL RHYTHMS
(2023)
Article
Clinical Neurology
Tobias Di Marco, Thomas E. Scammell, Michael Meinel, Dalma Seboek Kinter, Alexandre N. Datta, Gary Zammit, Yves Dauvilliers
Summary: The study aimed to explore the effect of daridorexant, a dual orexin receptor antagonist, on nighttime wake bouts and their correlation with daytime functioning. Results showed that daridorexant reduced the number and duration of long wake bouts during the night compared with placebo, corresponding with improved daytime functioning.